[13]CHEN S, WU J L, LIANG Y, et al. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site - ScienceDirect [J]. 分子细胞生物学报：英文版, 2021, 13(2): 3.[14] SYNNOTT N C, O'CONNELL D, CROWN J, et al. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells [J]. Breast cancer ...
6、Integrated analysis reveals TP53 mutation as a biomarker of anti-PD-1/PD-L1 treatment for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients.
如果获得批准,将eprenetapopt和阿扎胞苷方案用于移植后维持治疗可能代表一种新的治疗范式,有意义地改善治疗选择有限的患者的结局。 原文出处:Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML 注:本文...
Hao XZ, Wang Y. Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer. Thorac Cancer. 2023 Jul 5. doi: 10.1111/1759-7714.15021. Epub ahead of print. PMID: 37407282.
6、Integrated analysis reveals TP53 mutation as a biomarker of anti-PD-1/PD-L1 treatment for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients.
6、Integrated analysis reveals TP53 mutation as a biomarker of anti-PD-1/PD-L1 treatment for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients.
6、Integrated analysis reveals TP53 mutation as a biomarker of anti-PD-1/PD-L1 treatment for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients.